Cytokine Profiles at Admission Can Be Related to Outcome in AIDS Patients with Cryptococcal Meningitis

Delio José Mora1*, Laila Rigolin Fortunato1, Leonardo Eurípedes Andrade-Silva1, Kennio Ferreira-Paim1, Ivonete Helena Rocha1, Rakel Rocha Vasconcelos1, David Nascimento Silva-Teixeira1, Gabriel Antonio Nogueira Nascentes2, Mario León Silva-Vergara1*

1 Infectious Diseases Unit, Internal Medicine Department, Triângulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil, 2 Federal Institute of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil

* marioleon.dip@mednet.com.br (MLS-V); delioj@gmail.com (DJM)

Abstract

Cryptococcal meningitis (CM) remains as common life-threatening AIDS-defining illness mainly in resource-limited settings. Previous reports suggested that baseline cytokine profiles can be associated to fungal burden and clinical outcome. This study aimed to evaluate the baseline cytokine profiles in AIDS patients with CM and its relation with the outcome at weeks 2 and 10. Thirty AIDS patients with CM diagnosed by cerebrospinal fluid (CSF) Cryptococcus neoformans positive culture, India ink stain and cryptococcal antigen test were prospectively evaluated. As controls, 56 HIV-infected patients without CM and 48 non-HIV individuals were included. Baseline CSF and sera levels of IL-2, IL-4, IL-8, IL-10, IL-12p40, IL-17A, INF-γ and TNF-α were measured by ELISA. Of 30 CM patients, 24 (80%) were male, median age of 38.1. The baseline CSF high fungal burden and positive blood culture were associated with a positive CSF culture at week 2 (p = 0.043 and 0.029). Most CSF and sera cytokines presented higher levels in CM patients than control subjects (p < 0.05). CSF levels of IL-8, IL-12p40, IL-17A, INF-γ and TNF-α were significantly higher among survivors at weeks 2 and 10 (p < 0.05). Patients with increased intracranial pression exhibited CSF IL-10 high levels and poor outcome at week 10 (p = 0.032). Otherwise, baseline CSF log10 IFN-γ and IL-17A were negatively correlated with fungal burden (r = -0.47 and -0.50; p = 0.0175 and 0.0094, respectively). The mortality rate was 33% (10/30) at week 2 and 57% (17/30) at week 10. The severity of CM and the advanced immunodeficiency at admission were related to a poor outcome in these patients. Otherwise, the predominant Th1 cytokines profile among survivors confirms its pivotal role to infection control and would be a prognostic marker in cryptococcal meningitis.
Introduction

Cryptococcal meningitis (CM) is a common life-threatening fungal infection in AIDS patients and represents a medical, social and economic high burden due to its unacceptable 60% mortality rate [1,2]. This occurs particularly in poor-resources settings where most individuals present late HIV diagnosis and severe fungal disease at admission together with a limited access to anti-retroviral (ART) and ideal antifungal therapy [1–3]. Otherwise, in high-income countries, CM number of cases and mortality rate declined significantly following introduction of more effective ART and a gold standard antifungal therapy [4,5].

Yearly, at least one million of cryptococcosis cases occur around the world, mostly in HIV infected individuals of whom 620,000 die, predominantly in sub-Saharan Africa where the mortality overpasses that associated to tuberculosis despite the expansion of ART programs and FLZ availability during the last years [2,6]. Latin America is the third global region with high incidence and a 10-week mortality rate of 30 to 55% [7–9].

In order to understand the poor outcome of CM patients, several clinical and laboratory features have been evaluated as prognostic markers such as: to be naive to ART, altered consciousness, abnormal brain imaging at computerized tomography (CT) scan and/or magnetic resonance imaging (MRI), elevated intracranial pressure (ICP) and disseminated infection at admission [3,10–13]. Furthermore, CD4+ T count < 100 cells/mm³, CSF white blood cell (WBC) count ≤ 20 cells/μL, CSF culture >10⁶ CFU/mL with positive India ink stain, paucity of Th1 pattern cytokine release and infection with C. neoformans var. grubii (serotype A) have been also considered [14–16].

Similar to other chronic fungal and mycobacterial diseases, cryptococcal infection clearance is associated with granulomatous inflammatory reaction and depends on coordinated interaction of innate and adaptive immune response mediated by CD4+ and CD8+ T-cells to establish a type 1 helper T cells (Th1) response [17–19]. This protective immune response involves the releasing of cytokines such as tumor necrosis factor α (TNF-α), interleukin 8 (IL-8), IL-6, IL-12 and interferon γ (IFN-γ) which lead to classical activation of macrophages and their recruitment to the infection site [14,19,20].

In contrast, high levels of IL-4, IL-5, IL-10 and IL-13 have been related to inadequate IFN-γ production and alternatively activation of macrophages leading to uncontrolled fungal infection [21–23]. This fact has been attributed to immune modulatory properties of capsular cryptococcal antigen (CrAg) continuously released favoring the yeast escape from the immune system [24,25]. Moreover, it has been associated with raised ICP, immune reconstitution inflammatory syndrome (IRIS), disease severity and a poor outcome [26–28]. Of note, in animal models, IL-17A high levels were associated with reduced fungal burden and a protective immune response against pulmonary infection with C. neoformans H99γ [29]. However the role of these cytokines in patients with cryptococcal infection is yet to be elucidated [30].

This study aimed to evaluate the baseline CSF and sera cytokines and their relation with clinical and laboratory features and outcome in AIDS patients with cryptococcal meningitis.

Methods

Subjects

This study was carried out from August 2008 to November 2012 at the Teaching Hospital of Triângulo Mineiro Federal University in Uberaba, Minas Gerais State, Brazil. Thirty out of 38 AIDS-patients aged ≥ 18 years presenting CM (CM+ HIV+) were prospectively enrolled. Cryptococcal meningitis case was defined on clinical and laboratory features including positive CSF India ink stain, CrAg test and Cryptococcus neoformans culture [31]. Demographic,
epidemiological, clinical, laboratory and outcome data were obtained from their medical records. As controls to CSF and sera baseline cytokines assessment, 56 HIV-positive individuals without CM (CM- HIV+) matched by CD4+ T-cells count, age and gender admitted at the hospital due to several infectious such as: toxoplasmosis, chagas disease, syphilis, tuberculosis, cytomegalovirus (CMV) and *Paracoccidioides brasiliensis* or non-infectious neurological clinical pictures such as: epilepsy, migraine, stroke, dementia, among others were included. These patients required lumbar puncture for elucidative clinical diagnosis and a CSF aliquot was collected for this study. Otherwise, another control group was formed by 48 HIV-negative patients without cryptococcosis (CM- HIV-) admitted to the emergency room for several reasons such as: migraine, epilepsy, tension-type headache, among others were included. During clinical evaluation, these patients performed lumbar puncture and a CSF aliquot was collected for this study (Table 1).

The HIV infection status was defined by two enzyme-linked immunoassay tests (ELISA) (Welcozyme, Wellcome diagnostics, Dart ford, Oxford, UK) and confirmed by Western blot. Written informed consent of patients and controls was provided. The study was approved by the Research Ethical Board of the Triângulo Mineiro Federal University (protocol #1350).

## Laboratory assessment

Both blood and CSF samples of CM patients and controls were simultaneously obtained at admission. The CSF samples (5–10 mL) were divided in two parts; the first was used to perform cell count, biochemical assessment, cryptococcal antigen (CrAg) detection and quantitative fungal culture. The second was aliquoted (200μL/vial) and stored at -70°C to cytokine assessment. The blood samples (5–10 mL) were centrifuged and sera was aliquoted (200μL/vial) and

### Table 1. Demographic, clinical and laboratory data of patients with cryptococcal meningitis and the control groups.

| Variables                        | CM+ HIV+ N = 30 | CM+ HIV+ N = 56 | CM- HIV- N = 48 |
|----------------------------------|-----------------|-----------------|-----------------|
| Age, years                       | 38.1 (25–50)    | 38.4 (31–44)    | 40.1 (33–47)    |
| Males N (%)                      | 24 (80)         | 37 (66)         | 38 (79.1)       |
| Years since HIV diagnosis        | 12.8 (9.3–18.4) | 10.5 (7.1–17.8) | —               |
| CD4+ T-cells count, cells/mm³    | 36 (19–75)      | 39.4 (25–54)    | —               |
| HIV load, log_{10} copies/mL     | 5.1 (4.3–5.9)   | 5 (5–5.1)       | —               |

Data presented are median [interquartile range, (IQR)] or percentage (No.). Groups are comparable in CD4+ T-cell count and HIV load in blood (p = 0.027 and 0.042, respectively).

Abreviations: CM+ HIV+, HIV-infected patients with cryptococcal meningitis; CM+ HIV+, HIV-infected individuals without cryptococcal meningitis; CM- HIV+; HIV-negative individuals without cryptococcosis.

**CM+ HIV+ control group clinical diagnoses:** syphilis (n = 7), encephalitis associated to HIV infection (n = 7), toxoplasmosis (n = 5), tension-type headache (n = 5), dementia associated to HIV (n = 5), asseptic meningitis (n = 4), progressive multifocal leucoencephalopathy (n = 3), *mycobacterium* disease (n = 2), viral encephalitis (n = 2), epilepsy (n = 2), cerebral primary lymphoma (n = 2), migraine (n = 2), stroke (n = 1), encephalitis by *T. cruzi* (n = 1), encephalitis by *Paracoccidioides brasiliensis* (n = 1), cerebral nocardiosis (n = 1), guillain-barré syndrome (n = 1), encephalitis by CMV (n = 1), sepsis (n = 1), glaucoma (n = 1), hypertensive encephalopathy (n = 1), unknown paresis (n = 1).

**CM+ HIV+ control group clinical diagnoses:** epilepsy (n = 10), migraine (n = 7), stroke (n = 6), tension-type headache (n = 6), skull trauma (n = 6), alcoholism (n = 5), dementia (n = 2), systemic eritematosus lupus (n = 1), hipertensive encephalopathy (n = 1), asseptic meningitis (n = 1), viral encephalitis (n = 1).

Abbreviations: CM+ HIV+, HIV-infected patients with cryptococcal meningitis; CM+ HIV+, HIV-infected individuals without cryptococcal meningitis; CM- HIV+; HIV-negative individuals without cryptococcosis.
stored at -70°C to further cytokine assessment and capsular antigen quantification. The CSF and sera CrAg titers were determined by the cryptococcal antigen latex detection system (IMMY Mycologics Inc, OK, USA) according to manufacturer’s protocol. This semiquantitative technique to determine the CrAg titer was based on the agglutination observed in serial dilutions of CSF and sera. The fungal identification included the presence of capsule by India ink stain, ability to produce melanin on Niger seed (Guizotia abyssinica) agar and urease production (Urease Christensen). L-Canavanine-glycine-bromothymol blue (CGB) agar and orotidine monophosphate pyrophosphorylase (URA5) gene restriction fragment length polymorphism (RFLP) analysis were used to identify Cryptococcus species and its genotype, respectively according to methodology already described [32,33].

Quantitative fungal culture was performed as described elsewhere [31]. Briefly, with a mean delay of < 1 h after lumbar puncture, 1 mL of CSF was diluted 10-fold in sterile saline and 100μL of each dilution were inoculated onto Sabouraud’s dextrose agar (SDA) plate (DIFCO, Detroit, Michigan). Plates were incubated at 30°C for 14 days and colonies counted at the lowest dilution to evidence discernible colonies which multiplied by the dilution, permits to obtain colony-forming units (CFU) per mL and then log_{10}-transformed.

Cytokine assays

Sera and CSF samples of CM patients and control subjects stored at -70°C were used to evaluate cytokines levels through Enzyme-Linked Immunosorbent Assay (ELISA). Tumor necrosis factor-α (TNF-α), Interferon-γ (INF-γ), Interleukin-2 (IL-2), IL-4, IL-8, IL-10, IL-12p40, (Becton Dickinson, USA) and IL-17A (R&D Systems, USA) levels were quantified using the luminometer (Turner Biosystems, Sunnyvale, CA, USA). Briefly, 96-well half area flat-bottomed plates (Costar, Corning, NY) were prepared by coating the wells overnight at 4°C with 35μL of a Capture Antibody Purified Anti-human for each cytokine in Coating Buffer (1:250). Each well was washed 5 times (150 μL/well) with PBS-Tween wash solution (PBS/0.05% Tween 20) and then blocked with 100μL/well of PBS/2% BSA for 4 h at room temperature. After well washing for 5 times with wash solution, 25μL of test samples diluted in assay buffer (25μL PBS/1% BSA) or cytokine standards (serial dilution 1:2) were added to washed wells and incubated overnight at 4°C. Washed wells were incubated with 35μL of Detection Antibody Biotin Anti-human for each cytokine (1:500) and Enzyme Concentrate Streptavidin-HRP (1:250) in assay buffer (PBS/1% BSA) for 2 h at 37°C. The plates were again washed five times and added 50μL of freshly mixed TMB peroxidase solutions A and B (1:1 [vol/vol]) per well at room temperature. The reaction was stopped after 5 min by the addition of 50 μL of 1 M sulfuric acid per well and the color absorbance was read at OD 405 and 490 nm (Abs405—Abs490). The results were expressed in picograms per milliliter based on a standard curve.

Statistical analysis

Continuous variables with normal distribution were analyzed by Student’s t-test, and continuous variables with abnormal distribution were analyzed by the Mann-Whitney U-test. Correlations to continuous variables were tested for significance through the Spearman rank and Pearson’s tests. Cytokine median levels were compared by the Mann-Whitney U-test or Kruskal-Wallis test with Dunn’s multiple, depending on the groups’ number. The association between baseline cytokine levels and CrAg titers with mortality at weeks 2 and 10 was evaluated by Mann-Whitney U test. The Kaplan-Meier method and the log-rank test were used to evaluate the cumulative survival by univariate analysis at weeks 2 and 10 according to clinical and laboratory parameters. Factors significantly associated with risk of death by univariate analysis underwent a multivariate analysis using Cox proportional-hazards regression models to
identify parameters that were independently related to mortality. The Hazard ratio (HR) was estimated by the uni- and multivariate analysis with 95% confidence interval to show the effect of each variable on the death risk at weeks 2 and 10. Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, 2008), MedCalc for Windows version 11.3 (MedCalc Software, Ostend, Belgium) and GraphPad Prism v5 (GraphPad software Inc, CA USA). For all tests, p values < 0.05 were considered significant.

Results

Baseline epidemiological, clinical and laboratory data

Of 30 AIDS-patients with CM, 24 (80%) were male, mean age of 38.1 years (interquartile range [IQR, 25–50]). Cryptococcal meningitis was the first AIDS-defining disease in 17 (56.6%) cases, while in 11 (64.7%) both diagnoses were simultaneously performed at admission. The median CD4+ cell count was 36/mm3 [IQR, 19–75] and the median HIV load was 5.1 log_{10} ARN copies/mL [IQR, 4.3–5.9]. The most prevalent category risk to HIV infection was heterosexual unprotected intercourse present in 26 (86.6%) individuals of whom 13 (50%) were also illicit drug users. All clinical isolates were characterized as C. neoformans, VNI genotype.

At admission, clinical features such as: headache, fever, stiff neck, weight loss, altered consciousness and increased ICP were present in 26 (86.6%), 23 (76.6%), 22 (73.3%), 22 (73.3%), 19 (63.3%) and 18 (60%) individuals respectively. Mean time between onset of symptoms and hospitalization was 16.2 days (range, 4–27). Analysis of CSF baseline showed ≥ 5 log_{10} CFU/mL, CrAg titer ≥ 1:1024 and WBC count < 20 cells/μL in 20 (66.6%), 20 (66.6%) and 16 (53.3%) of cases, respectively. The mean CSF protein concentration in CM patients (92 mg/dL [IQR, 61–119]) was significantly elevated compared with 34 mg/dL in CM- HIV+ and 42 mg/dL in CM- HIV-controls (p < 0.001). The mean CSF glucose of (26.4 mg/dL [IQR, 18–50.4]) in CM patients was significantly lower compared with 49.7 mg/dL in CM- HIV+ and 51.6 mg/dL in CM- HIV- subjects (p = 0.043). The protein concentration in CM patients was significantly correlated with the CrAg titers (r = 0.78, p = 0.032).

Clinical and laboratory features vs outcome

Patients with papilledema, weight loss and cranial nerves palsies at admission presented increased risk of death at weeks 2 through univariate analysis (all p ≤ 0.03) whereas, stiff neck, papilledema, weight loss, cranial nerves palsies, increased ICP and cryptococcal meningitis as first AIDS definition disease were associated to a poor outcome at week 10 (all p < 0.05, Table 2). Mortality rate of 33% (10/30) and 57% (17/30) were observed at weeks 2 and 10 on therapy, respectively. Four patients died before antifungal therapy. Among patients with increased ICP, eight (44.4%) performed repeated relief lumbar punctures. Of 26 patients on therapy, 20 (76.9%) received Amphotericin B (AmB) during 14 days and after this fluconazole 400 mg twice a day for eight weeks. The remaining six patients received AmB plus fluconazole for 14 days followed by fluconazole 400 mg twice a day for eight weeks. No cases of immune reconstitution inflammatory syndrome (IRIS) were diagnosed among these patients. Besides, none of them received corticosteroid therapy.

The univariate analysis, showed patients who presented baseline CSF ≥ 5 log_{10} CFU/mL and CrAg titer > 1:1024 had a 5.9-fold increased risk to death at week 2 (p = 0.092). Similarly, patients with CSF ≥ 5 log_{10} CFU/mL, CrAg titer > 1:1024 and fungaemia survived less at week 10 (all p < 0.04, Table 3). Individuals with baseline CSF high fungal burden and positive blood culture presented positive CSF culture at week 2 on therapy (p = 0.043 and 0.029, respectively), while sera CrAg titers were higher in patients with fungaemia (1:2048 vs. 1:64, p < 0.001). The CSF culture was negative in 12/20 (60%) and 11/13 (84.6%) at weeks 2 and 10, respectively. In
Table 2. Clinical features at admission associated with outcome at 2 and 10 weeks in 30 AIDS-patients with cryptococcal meninigitis.

| Clinical data          | 2-week mortality | 10-week mortality |
|------------------------|------------------|-------------------|
|                        | N (%) p-univariate HR (95% CI) | N (%) p-univariate HR (95% CI) |
| Gender                 |                  |                   |
| Female                 | 2/6 (33.3) 0.933 0.94 (0.20–4.41) | 3/6 (50.0) 0.824 1.15 (0.33–4.01) |
| Male                   | 8/24 (33.3)      | 14/24 (58.3)      |
| Headache               |                  |                   |
| No                     | 1/4 (25.0) 0.645 1.62 (0.21–12.84) | 2/4 (50.0) 0.610 1.47 (0.34–6.44) |
| Yes                    | 9/26 (34.6)      | 15/26 (57.7)      |
| Fever                  |                  |                   |
| No                     | 2/7 (28.6) 0.827 1.19 (0.25–5.60) | 4/7 (57.1) 0.920 1.06 (0.34–3.25) |
| Yes                    | 8/23 (34.8)      | 13/23 (56.5)      |
| Stiff neck             |                  |                   |
| No                     | 1/8 (12.5) 0.235 3.50 (0.44–27.65) | 1/8 (12.5) 0.040 8.40 (1.11–63.85) |
| Yes                    | 9/22 (40.9)      | 16/22 (72.7)      |
| Papilledema            |                  |                   |
| No                     | 2/19 (10.5) 0.001 12.77 (2.65–61.45) | 8/19 (42.1) 0.002 4.86 (1.82–13.01) |
| Yes                    | 8/11 (72.7)      | 9/11 (81.8)       |
| Vomit                  |                  |                   |
| No                     | 5/21 (23.8) 0.083 3.01 (0.87–10.41) | 11/21 (52.4) 0.221 1.87 (0.69–5.07) |
| Yes                    | 5/9 (55.6)       | 6/9 (66.7)        |
| Weigh loss             |                  |                   |
| No                     | 0/8 (0.0) 0.030 4.45 (1.16–17.15) | 2/8 (25.0) 0.046 4.52 (1.03–19.93) |
| Yes                    | 10/22 (45.5)     | 15/22 (68.2)      |
| Altered consciousness  |                  |                   |
| No                     | 3/11 (27.3) 0.617 1.41 (0.36–5.46) | 4/11 (36.4) 0.143 2.32 (0.75–7.15) |
| Yes                    | 7/19 (36.8)      | 13/19 (68.4)      |
| Cranial nerves palsies |                  |                   |
| No                     | 3/18 (16.7) 0.021 4.98 (1.27–19.43) | 6/18 (33.3) 0.001 6.01 (2.11–17.14) |
| Yes                    | 7/12 (58.3)      | 11/12 (91.7)      |
| Nausea                 |                  |                   |
| No                     | 9/20 (45.0) 0.118 0.19 (0.02–1.52) | 13/20 (65.0) 0.216 0.49 (0.16–1.51) |
| Yes                    | 1/10 (10.0)      | 4/10 (40.0)       |
| Increased ICP          |                  |                   |
| No                     | 1/12 (8.3) 0.059 7.34 (0.93–58.05) | 4/12 (33.3) 0.032 3.46 (1.11–10.74) |
| Yes                    | 9/18 (50.0)      | 13/18 (72.2)      |
| Seizures               |                  |                   |
| No                     | 6/22 (27.3) 0.336 1.86 (0.53–6.60) | 10/22 (45.5) 0.069 2.47 (0.93–6.57) |
| Yes                    | 4/8 (50.0)       | 7/8 (87.5)        |
| First AIDS defining disease |        |                   |
| No                     | 2/13 (15.4) 0.079 4.02 (0.85–18.97) | 5/13 (38.5) 0.049 2.88 (1.01–8.23) |
| Yes                    | 8/17 (47.1)      | 12/17 (70.6)      |

Abbreviations: HR, Hazard ratio; CI, confidence interval; ICP, increased intracranial pressure.

doi:10.1371/journal.pone.0120297.t002
addition, patients with persistent positive culture at week 2 were also associated to a poor outcome at week 10 (p = 0.039). Otherwise, baseline high fungal burden presented increased risk of death at weeks 2 and 10 (p = 0.023 and 0.034, respectively).

In a multivariable regression cox model based on clinical and laboratory parameters, papilledema and cranial nerves palsies were statistically associated to mortality at weeks 2 and 10 (all p < 0.02) whereas altered consciousness and fungaemia at week 10 (all p ≤ 0.02, Table 4).

### Table 3. Laboratory features at admission associated with outcome at 2 and 10 weeks in 30-AIDS patients with cryptococcal meningitis.

| Laboratory data | 2-week mortality | 10-week mortality |
|-----------------|------------------|-------------------|
|                 | N (%) | p-univariate | HR (95% CI) | N (%) | p-univariate | HR (95% CI) |
| CD4+ (cells/mm³) |       |              |            |       |              |            |
| > 100           | 3/7 (42.9) | 0.613 | 0.70 (0.18–2.73) | 3/7 (42.9) | 0.572 | 1.43 (0.41–5.00) |
| ≤ 100           | 7/23 (30.4) |              |            | 14/23 (60.9) |              |            |
| HIV load (RNA/mL) |       |              |            |       |              |            |
| < 30,000        | 3/7 (42.9) | 0.809 | 0.85 (0.22–3.28) | 6/7 (85.7) | 0.211 | 0.53 (0.19–1.44) |
| ≥ 30,000        | 7/23 (30.4) |              |            | 11/23 (47.8) |              |            |
| log₁₀ CFU/mL |        |              |            |        |              |            |
| < 5 log₁₀       | 1/10 (10.0) | 0.092 | 5.91 (0.75–46.81) | 3/10 (30.0) | 0.041 | 3.68 (1.05–12.90) |
| ≥ 5 log₁₀       | 9/20 (45.0) |              |            | 14/20 (70.0) |              |            |
| CrAg titer |        |              |            |        |              |            |
| < 1:1024        | 1/10 (10.0) | 0.092 | 5.91 (0.75–46.81) | 3/10 (30.0) | 0.041 | 3.68 (1.05–12.90) |
| ≥ 1:1024        | 9/20 (45.0) |              |            | 14/20 (70.0) |              |            |
| CSF-WBC count |        |              |            |        |              |            |
| ≥ 20 cells/μL   | 2/14 (14.3) | 0.058 | 4.49 (0.95–21.24) | 6/14 (42.9) | 0.088 | 2.39 (0.88–6.51) |
| < 20 cells/μL   | 8/16 (50.0) |              |            | 11/16 (68.8) |              |            |
| CSF glucose |        |              |            |        |              |            |
| ≥ 50 mg/dL      | 3/8 (37.5) | 0.840 | 0.87 (0.22–3.37) | 3/8 (37.5) | 0.338 | 1.84 (0.53–6.42) |
| ≤ 50 mg/dL      | 7/22 (31.8) |              |            | 14/22 (63.6) |              |            |
| CSF protein |        |              |            |        |              |            |
| ≤ 40 mg/dL      | 2/8 (25.0) | 0.550 | 1.60 (0.34–7.56) | 3/8 (37.5) | 0.274 | 2.01 (0.58–7.00) |
| ≥ 40 mg/dL      | 8/22 (36.4) |              |            | 14/22 (63.6) |              |            |
| Fungaemia |        |              |            |        |              |            |
| No              | 6/18 (33.3) | 0.756 | 1.22 (0.34–4.34) | 6/18 (33.3) | 0.008 | 3.96 (1.44–10.88) |
| Yes             | 4/12 (33.3) |              |            | 11/12 (91.7) |              |            |

Abbreviations: HR, Hazard ratio; CI, confidence interval; WBC, white blood cell; CFU, Colony-forming units; CSF, cerebrospinal fluid; ICP, increased intracranial pressure; CrAg, cryptococcal glucuronoxylomannan antigen.

doi:10.1371/journal.pone.0120297.t003

| Variable | 2-week mortality | 10-week mortality |
|----------|------------------|-------------------|
|          | p-value | Adjusted HR (95% CI) | p-value | Adjusted HR (95% CI) |
| Papilledema | 0.001 | 21.02 (3.31–133.44) | < 0.001 | 24.03 (4.97–116.21) |
| Cranial nerves palsies | 0.014 | 8.58 (1.55–47.39) | 0.001 | 9.48 (2.61–34.47) |
| Altered consciousness | - | - | 0.023 | 5.07 (1.26–20.38) |
| Fungaemia | - | - | 0.007 | 5.69 (1.61–20.10) |

doi:10.1371/journal.pone.0120297.t004
Cerebrospinal fluid and sera cytokine profile and outcome

At admission, CM⁺ HIV⁺ patients presented CSF higher levels of IL-2, IL-4, IL-8, IL-10, IL-17A, IFN-γ and TNF-α than CM⁻ HIV⁻ ones and higher levels of IL-2, IL-8, IL-17A, IFN-γ and TNF-α than CM⁻ HIV⁺ control. Individuals with CM⁺ HIV⁺ presented higher levels of IL-4 and IL-17A than CM⁻ HIV⁻ ones. Levels of IL-17A were significantly different among the three groups (Fig. 1).

The sera cytokines median levels in CM⁺ HIV⁺ patients were higher than the controls, except IL-4 and IL-12p40 which were increased in CM⁻ HIV⁺ and CM⁻ HIV⁻, respectively. The IL-8, IL-10, IL-12p40, IL-17A and IFN-γ levels were significantly higher in CM⁺ HIV⁺ than CM⁻ HIV⁻ individuals. Also, IL-4, IL-8 and TNF-α levels were higher in CM⁻ HIV⁺ than CM⁻ HIV⁻ controls. The IL-8 levels were significantly different among the three groups (Fig. 1).

The comparison between baseline CSF and sera cytokines levels of 20 survivors and 10 fatalities at week 2 showed CSF high levels of IL-8, IL-12p40, IL17-A, IFN-γ, TNF-α and higher sera TNF-α level among survivors (all p ≤ 0.04, Fig. 2). In contrast, fatal cases presented two-fold increased CSF and sera median levels of IL-4 at week 2 and 10 and two-fold increased of CSF IL-10 levels than survivors at week 2 (all p ≤ 0.03, Fig. 2). Besides, sera IL-2, IL-8, IL-10, IL-12p40, IL-17A IFN-γ and IL-2 CSF levels were not significantly different between survivors and fatal cases.

Overall, CM patients who survived through week 10 had higher baseline CSF levels of: IL-8, IL-12p40, IL-17A, IFN-γ and TNF-α (all p ≤ 0.04, Fig. 3). Likewise, IL-2, IL-8, IL-12p40 and TNF-α high sera levels were also associated with higher survival rate at week 10, whereas a two-fold increased levels of IL-4 was associated to a poor outcome (all p ≤ 0.04, Fig. 3). In addition, patients with fungaemia presented higher IL-10 and lower IL-12p40/IL-10 sera levels (p = 0.046 and 0.039, respectively).

Individuals with CSF persistent positive culture at week 2 presented higher baseline levels of IL-4 and IL-10, as well as lower levels of IFN-γ, IL-12p40 and IL-17A (all p ≤ 0.05). Conversely, those with CSF negative culture at week 2 exhibited high levels of IFN-γ, IL-8 and IL-17A at admission (all p ≤ 0.04). The IFN-γ and IL-17A were negatively correlated with the CFU/mL, while IL-4 and IL-10 were positively correlated with high fungal burden and CrAg (Fig. 4).

Discussion

The epidemiological, clinical and outcome profile of patients with CM associated to AIDS herein described resembled that observed in other Brazilian, Latin America and sub-Saharan Africa regions [8,12,34,35]. Most of them were adult male, median age, presenting late HIV diagnosis and severe and disseminated fungal disease at admission [15,36,37].

In CM patients, increased ICP leads to papilledema, vomits and can contribute to altered consciousness status at admission which have been correlated to a poor outcome at weeks 2 and 10 as evidenced in most patients of this study [1,3,16,27]. The increased ICP occurs as a consequence of CSF outflow obstruction caused by the inflammatory reaction, with yeasts and/or CrAg accumulation at the arachnoid villi and subarachnoid spaces [27,38]. This fact can support the positive correlation between fungal burden with increased ICP observed in these cases [14–16,27,38]. According with several authors, mortality within 2 weeks on antifungal therapy is closely related to cryptococcal infection, different from that occurring after this period which is more related to other HIV complications [12,16].

The interaction between Cryptococcus spp. and the host’s immune system is a major determinant for the outcome of the disease [39,40]. In the last decades, several studies have demonstrated the protective effect of proinflammatory cytokines during clinical and experimental cryptococcal infection and its potential as adjuvant for immunotherapy [14,23,41,42].
However, clinical studies correlating the baseline cytokine profiles with fungal burden and clinical outcome are scarce and this issue needs to be better elucidated [14, 16].

Cell-mediated immunity and its related cytokines are the most important arm against *C. neoformans* and during HIV infection, patients exhibit a switch towards a Th2 response.
Fig 2. Baseline cerebrospinal fluid (CSF) and sera cytokines levels (pg/mL) in survivors (n = 20) and fatal cases (n = 10) at 2 week. Data are shown as boxes: internal horizontal lines, medians; tops and bottom of boxes, 25th and 75th percentiles, respectively. Upper and lower bars, tenth and 90th percentiles, respectively. Statistical comparisons were made using the Mann-Whitney U test.

doi:10.1371/journal.pone.0120297.g002
Fig 3. Baseline cerebrospinal fluid (CSF) and sera cytokines levels (pg/mL) in survivors (n = 13) and fatal cases (n = 17) at 10 weeks. Data are shown as boxes: internal horizontal lines, medians; tops and bottom of boxes, 25th and 75th percentiles, respectively. Upper and lower bars, tenth and 90th percentiles, respectively. Statistical comparisons were made using the Mann-Whitney U test.
doi:10.1371/journal.pone.0120297.g003
inhibiting cellular immune response evidenced by IL-12 and IFN-γ lower levels, as well as, IL-4 and IL-10 increased levels which are associated with progression to AIDS [43–46].

The polysaccharide capsule of *Cryptococcus* spp. is considered its major virulence factor by inducting IL-10 secretion by mononuclear cells which facilitates the evasion of host defenses, inhibits the TNF-α and IFN-γ production and favors the paucity of leukocytes leading to unchecked proliferation of yeast cells [25,47–49]. Furthermore, it enhances the infectivity of HIV increasing the affinity of gp120 binding to the CD4+ receptor [50]. The CSF IL-10 high levels and significantly lower rate ratios of IFN-γ/IL-10 and IL-2/IL-10 observed among CM patients suggest Th1 dysregulation is pivotal and may contribute to CM pathogenesis in AIDS patients similar to that described in transplanted patients and those with idiopathic CD4 lymphopenia [42,51].

Different from immunocompetent individuals or those with other T cell immune deficiencies, AIDS patients with CM often present a CSF minimal cellularity related to advanced
immunosuppression, as corroborated by the CD4+ T cells baseline count < 100 cells/mm³ observed in 76.7% of individuals [4,10,15]. Otherwise, most of them exhibited CSF IL-8 high levels which would favor the leukocyte migration through the blood-brain barrier. However, this action is avoided by circulating CrAg through shedding L-selectin from leukocytes surface impeding them to bind to endothelial cells and consequently to reach the CNS [24,52]. This feature is in line with previous studies in which the lack of correlation between CSF cellularity and baseline cytokine levels suggests these mediators are locally produced by activated resident cells as microglia, astrocytes and immunoregulatory NK, independently of the attracted mononuclear cells [39,40].

Cerebrospinal fluid cytokines levels and fungal load were evaluated at admission and related to outcome at weeks 2 and 10 on therapy. Survivor patients significantly presented higher CSF and sera baseline levels of TNF-α, IFN-γ and IL-8 confirming results of previous studies [14,16,41,53,54]. In addition, both IFN-γ and IL-17A levels were negatively correlated with the CSF baseline CFU count remarking their relevance to the infection control [23,29,55]. Otherwise the relatively high levels of IFN-γ and other proinflammatory cytokines observed in HIV-negative control patients can be related to their underlying diseases such as stroke, dementia, epilepsy as described elsewhere [56–58].

Although the role of Th17 cytokines in fungal immunity is not fully understood yet, previous studies have suggested that IL-17A production is related to the generation of protective immune response against C. neoformans and other intracellular pathogens as Pneumocystis jirovecii and Mycobacterium tuberculosis [29,59,60]. Experimentally, infected mice with C. neoformans H99γ, presented an increased production of IL-17, clearance of infection and a protective response against challenge with a wild-type strain reinfection [20]. These features reinforce the pivotal role of IFN-γ to control infection and suggest that IL-17 works together with other proinflammatory cytokines to modulate the immune response against Cryptococcus spp. [14,29,55].

Conversely, among fatal cases a 2-fold increase of anti-inflammatory cytokines IL-4 and IL-10 levels in both sera and CSF was positively correlated with severe and disseminated infection and high CSF fungal burden [14,19]. The IL-4 production mediated by polysaccharide capsule inhibits the differentiation of naïve CD4+ T cells (Th0) to Th1, and consequently INF-γ production, which stimulates the anti-cryptococcal activity in macrophages to destroy phagocyted microorganisms [46,61], whereas IL-10 inhibits lymphoproliferation, cytokine synthesis and expression of class II major histocompatibility complex molecules [42,62].

Recently, therapy based on cytokines has also been proposed as adjuvant in clinical and experimental cryptococcal meningitis [42,63–65]. The relevance of IFN-γ as inductive therapy aiming a faster fungal clearance from CSF improving the rate survival was remarked [63–65]. In addition, administration of recombinant IFN-γ improved clinical and immunological parameters and potentiated the effects of FLZ and AmB [42,66]. This finding was validated through a randomized and controlled trial using IFN-γ together with AmB and 5-FC in AIDS patients with CM. Moreover, it was observed an increase of the rate of fungal clearance in 30% of cases who received both therapies compared with those who received conventional therapy only [64]. Furthermore, in a murine model of pulmonary cryptococcal infection, early infusion of IL-12 increased the recruitment of inflammatory cells, enhanced the activity of FLZ, prevented the dissemination and reduced the fungal burden in lungs and brain [67,68].

Most patients herein reported had an early CM diagnosis and started antifungal therapy based on AmB and half of them died at week 10 on therapy. This mortality rate is unacceptably high and paradoxal in Brazil where the ART has been freely available in the health public services since 1996. However, most of them presented late AIDS diagnosis, severe fungal infection and received suboptimal antifungal therapy which explains this figure. Despite a low number of patients evaluated it was possible to show that cytokine profile at admission is correlated
with clinical and laboratory findings which suggests that these immune mediators could be considered as markers of outcome at weeks 2 and 10 in AIDS patients with cryptococcal meningitis.

Acknowledgments
We thank to Miss Angela Azor for the technical assistance and all the volunteers that donated blood and cerebrospinal fluid samples for this study.

Author Contributions
Conceived and designed the experiments: DJM MLS-V. Performed the experiments: DJM LRF IHR RRV LEA-S KF-P MLS-V. Analyzed the data: DJM GANN MLS-V. Contributed reagents/materials/analysis tools: DJM DNS-T MLS-V. Wrote the paper: DJM MLS-V.

References
1. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of Mortality in a Combined Cohort of 501 Patients with HIV-associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clin Infect Dis. 2013; 56: 736–745. doi:10.1093/cid/cit794 PMID: 24319084
2. Antinori S. New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS. 2013; 25: 471363.
3. Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. 2011; 22: 665–670. doi:10.1258/ijsa.2011.010538 PMID: 22096053
4. Chuang YM, Ku SC, Liaw SJ, Wu SC, Ho YC, Yu CJ, et al. Disseminated Cryptococcus neoformans var. grubii infections in intensive care units. Epidemiol Infect. 2010; 138: 1036–1043. doi:10.1017/S0950268809990926 PMID: 19796452
5. Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS One. 2013; 8: e56269. doi:10.1371/journal.pone.0056269 PMID: 23457543
6. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23: 525–530. doi:10.1097/QAD.0b013e328322f2a0c PMID: 19182676
7. Vidal JE, Penalva de Oliveira AC, Daurar RF, Boulware DR. Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis. 2013; 17: 353–362. doi:10.1016/j.bjidd.2012.10.020 PMID: 23665012
8. Lindenberg Ade S, Chang MR, Paniago AM, Lazera Mdos S, Moncada PM, Bonfim GF, et al. Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Rev Inst Med Trop Sao Paulo. 2008; 50: 75–78. PMID: 18488084
9. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010; 5: 18–26. doi:10.1097/COH.0b013e32833850f PMID: 20046144
10. Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, Andrade-Silveira LE, Nascentes GA, Silva-Vergara ML. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia. 2012; 173: 321–327. doi:10.1007/s11046-011-9504-9 PMID: 22130645
11. Brizardine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013; 8: e60431. doi: 10.1371/journal.pone.0060431 PMID: 2355970
12. Dammert P, Bustamante B, Ticona E, Llanos-Cuentas A, Huaroto L, Chávez VM, et al. Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole. J Infect. 2008; 57: 260–265. doi:10.1017/S0197457208002092 PMID: 18707764
13. Cachay ER, Caperna J, Sitapati AM, Jafari H, Kandel S, Mathews WC. Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis. AIDS Res Ther. 2010; 7: 29. doi: 10.1186/1742-6405-7-29 PMID: 20682061
14. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, Irving D, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005; 174: 1746–1750. PMID: 15661940
15. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007; 4: e21. PMID: 17284154

16. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009; 49: 702–709. doi: 10.1086/604716 PMID: 19613840

17. Buchanan KL, Doyle HA. Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun. 2000; 68: 456–462. PMID: 10639404

18. Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB. Generation of antifungal effector CD8(+) T cells in the absence of CD4(+) T cells during Cryptococcus neoformans infection. J Immunol. 2005; 174: 7920–7928. PMID: 15944298

19. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, et al. The phenotype of the Cryptococcus-specific CD4(+) memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis. 2013; 207: 1817–1828. doi: 10.1093/infdis/jit099 PMID: 23493728

20. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun. 2007; 75: 1453–1462. PMID: 17210668

21. Srikanth P, Castillo RC, Sridharan G, John TJ, Zachariah A, Mathai D, et al. Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India. Int J STD AIDS. 2000; 11: 49–51. PMID: 10667901

22. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol. 2005; 174: 1027–1036. PMID: 15634927

23. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol. 2009; 175: 2488–2500.

24. Ellerbroek PM, Walenkamp AM, Hoepelman AI, Coenjaerts FE. Effects of the capsular polysaccharides of the capsular polysaccharides on phagocyte migration and inflammatory mediators. Curr Med Chem. 2004; 11: 253–266. PMID: 14754421

25. Vecchiarelli A. Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit Rev Immunol. 2007; 27: 547–557. PMID: 18197800

26. Bouwale DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010; 7: e1000384. doi: 10.1371/journal.pmed.1000384 PMID: 21253011

27. Wijewardana I, Jarvis JN, Meintjes G, Harrison TS, Bicanic T. Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect. 2011; 63: 484–486. doi: 10.1016/j.jinf.2011.09.002 PMID: 21930156

28. Robertson EJ, Najjuka G, Roelfs MA, Akampurira A, Jain N, Anantharanjit J, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis. 2014; 209: 74–82. doi: 10.1093/infdis/jit435 PMID: 23945372

29. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One. 2011; 6: e17204. doi: 10.1371/journal.pone.0017204 PMID: 21359196

30. Wozniak KL, Kolls JK, Wormley FL Jr. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by γδ T cells. BMC Immunol. 2012; 13: 65. doi: 10.1186/1471-2172-13-65 PMID: 23216912

31. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004; 363: 1764–1767. PMID: 15172774

32. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982; 15: 535–537. PMID: 7042750

33. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003; 9: 189–195. PMID: 12603989
34. Kambugu A, Meya DB, Rhein J, O'Brien EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46: 1694–1701. doi: 10.1086/587667 PMID: 18433339

35. Nussbaum JC, Jackson A, Namarkin D, Phulusa J, Kenala J, Kanyemba C, et al. Combination fluconazole and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010; 50: 338–344. doi: 10.1086/649861 PMID: 20308244

36. Edwards VE, Sutherland JM, Tyer JH. Cryptococcosis of the central nervous system. Epidemiological, clinical, and therapeutic features. J Neurol Neurosurg Psychiatry. 1970; 33: 415–425. PMID: 553907

37. McClelland EE, Hobbs LM, Rivera J, Casadevall A, Potts WK, Smith JM, et al. The Role of Host Gender in the Pathogenesis of Cryptococcus neoformans Infections. PLoS One. 2013; 8: e63632. doi: 10.1371/journal.pone.0063632 PMID: 23741297

38. Loyse A, Wainwright H, Jarvis JN, Bicanic T, Meintjes G, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010; 24: 405–410. doi: 10.1097/QAD.0b013e328333c005 PMID: 19952714

39. Zhou Q, Gault RA, Kozel TR, Murphy WJ. Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells. J Immunol. 2007; 178: 5753–5761. PMID: 17442959

40. Naranbhai V, Chang CC, Durgiah R, Omarjee S, Lim A, Moosa MY, et al. Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. AIDS. 2014; 28: 657–666. doi: 10.1097/QAD.0000000000000200 PMID: 24451162

41. Lortholary O, Sitbon K, Dromer F, French Cryptococcosis Study Group. Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during AIDS-associated cryptococcosis. Clin Microbiol Infect. 2005; 11: 296–300. PMID: 15760426

42. Netea MG, Brouwer AE, Hoogendoorn EH, Van der Meer JW, Kolen M, Verweij PE, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin Infect Dis. 2004; 39: e83–87. PMID: 15494899

43. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001; 12(3): 133–150. PMID: 12959322

44. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology. 2009; 83: 3719–3733. doi: 10.1128/JVI.01844-08 PMID: 19176632

45. Osakwe CE, Bleotu C, Chifiruc MC, Grovea C, O elea D, Paraschiv S, et al. TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum Arch Microbiol Immunol. 2010; 69: 24–34. PMID: 21053761

46. Alfeld M, Addo MM, Kreuzer KA, Rockstroh JK, Dumoulin FL, Schliefer K, et al. T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J Acquir Immun Defic Syndr. 2000; 23: 287–294. PMID: 10836750

47. Ucker WC, Doyle HA, McCracken JP, Langois M, Buchanan KL. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol. 2005; 43: 27–38. PMID: 15712606

48. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis. 2004; 57: 137–145. PMID: 15329444

49. Voelz K, Lammas DA, May RC. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun. 2007; 75: 3450–3457. doi: 10.1128/IAI.00297-09 PMID: 19487474

50. Pietrella D, Kozel TR, Monari C, Bistoni F, Vecchiarelli A. Interleukin-12 counterbalances the deleterious effect of human immunodeficiency virus type 1 envelope glycoprotein gp120 on the immune response to Cryptococcus neoformans. J Infect Dis. 2001; 183: 51–58. PMID: 11087201

51. Singh N, Husain S, Limaye AP, Purseil K, Klintmalm GB, Pruett TL, et al. Systemic and cerebrospinal fluid T-helper cytokine responses in organ transplant recipients with Cryptococcus neoformans infection. Transpl Immunol. 2006; 16: 69–72. PMID: 16860707

52. Lipovsky MM, Gekker G, Su S, Ehrlich LC, Hoepelman AI, Peterson PK. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J Infect Dis. 1998; 177: 260–263. PMID: 9419203
53. Lortholary O, Dromer F, Mathoulin-Pélissier S, Fitting C, Improvisi L, Cavaillon JM, et al. Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. J Infect Dis. 2001; 183: 294–302. PMID:11110651

54. Chaka W, Heyderman R, Gangaaidzo I, Robertson V, Mason P, Verhoef J, et al. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin-8 levels. J Infect Dis. 1997; 176: 1633–1636. PMID:9395381

55. Bicanic T, Meintjes G, Wood R, Hayes M, Beke R, Bechter K, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or flucytosine. Clin Infect Dis. 2007; 45: 76–80. PMID:17554704

56. Maxeiner HG, Marion Schneider E, Kurfiss ST, Brettschneider J, Tumani H, Bechter K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine. 2014; 69: 62–67. doi:10.1016/j.cyto.2014.05.008 PMID: 25022963

57. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003; 10: 1581–1591. PMID:12871129

58. Mao LY, Ding J, Peng WF, Ma Y, Zhang YH, Fan W, et al. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. Epilepsia. 2013; 54: e142–145. doi:10.1111/epi.12337 PMID: 23944193

59. Rudner X, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun. 2007; 75: 3055–3061. PMID:17403873

60. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog. 2013; 9: e1003472. doi:10.1371/journal.ppat.1003472 PMID: 23853983

61. Stenzel W, Müller U, Köhler G, Heppner FL, Blessing M, McKenzie AN, et al. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol. 2009; 174: 486–496. doi:10.2353/ajpath.2009.080598 PMID: 19147811

62. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008; 226: 205–218. doi:10.1111/j.1600-065X.2008.00706.x PMID: 19161426

63. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004; 189: 2185–2191. PMID:15181565

64. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012; 26: 1105–1113. doi:10.1097/QAD.0b013e3283536a93 PMID: 22421244

65. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon treatment for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother. 2001; 45: 686–689. PMID:11181343

66. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother; 2000; 46: 437–442. PMID:10980171

67. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol. 1996; 104: 208–214. PMID:8625510

68. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother. 1994; 38: 460–464. PMID:7911289